Results 121 to 130 of about 6,042 (221)

Guselkumab (Tremfya) [PDF]

Dermatologie pro praxi, 2020
Jan Hugo, Spyridon Gkalpakiotis
openaire   +1 more source

Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical Trials

Rheumatology and Therapy
Introduction There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in the phase 3 DISCOVER-1 and -2, and ...
Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov, Mohamed Sharaf, Frédéric Lavie, Atul Deodhar   +8 more
doaj   +1 more source

Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis [PDF]

, 2021
Argenziano, G., Prignano, F.
core   +1 more source

บทบาทของยา Guselkumab ในการรักษาโรคสะเก็ดเงินชนิดผื่นหนา Role of Guselkumab for the Treatment of Plaque Psoriasis [PDF]

บทคัดย่อ   Guselkumab เป็นยารักษาโรคสะเก็ดเงินชนิดผื่นหนาระดับปานกลางถึงรุนแรงในผู้ใหญ่อายุ 18 ปีขึ้นไป ที่ต้องได้รับการรักษาด้วย systemic therapy หรือ phototherapy ซึ่งเป็นยารายการแรกในกลุ่ม Interleukin-23 inhibitor ที่ได้รับการอนุมัติจากองค ...
Suncharoen, Sirada
core   +1 more source

Psoriasis [PDF]

, 2016
Elder, James T., Finlay, Andrew Y., Gladman, Dafna D., Goldminz, Ari M., Gottlieb, Alice B., Greb, Jacqueline E., Lebwohl, Mark G., Mehta, Nehal N., Wu, Jashin J.   +8 more
core   +1 more source

First-Line Guselkumab Combined with Exclusive Enteral Nutrition in Biologic-Naïve Young‑Onset Crohn's Disease: A Three-Case Series from China. [PDF]

J Inflamm Res
Sha S, Xu B, Qiao C, Wang K, Liu L, Wu J, Ma W, Shi A, Liu X.   +8 more
europepmc   +1 more source

Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Wang S, Xu Y, Lin H, Zhang X, Ding J, Jiang H, Fan Y, Sun C.   +7 more
europepmc   +1 more source

Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions. [PDF]

J Pers Med
Pool IA, Otten AT, Kosterink JGW, Dijkstra G, Mian P, Bourgonje AR.   +5 more
europepmc   +1 more source

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis). [PDF]

Dermatol Ther (Heidelb)
Trovato E, Cartocci A, Gaiani F, Messina F, Mastorino L, Macagno N, Carugno A, Campoli M, Fargnoli MC, Lora V, Rossi A, Gioacchini H, Potestio L, D'Agostino GM, Maurelli M, Girolomoni G, Romanelli M, Dini V, Loconsole F, Satolli F, Pagnanelli G, Lasagni C, Michelerio A, Dragotto M, Malagoli P, Zerbinati N, Orsini D, Campanati A, Megna M, Bianchelli T, Italian Landscape Group, Costanzo A, Ribero S, Narcisi A.   +33 more
europepmc   +1 more source

Patient Satisfaction Using Guselkumab Self-administered Using the One-Press Device for Treatment of Moderate-to-Severe Psoriasis: Results from a National, Prospective, Real-World Study in Portugal (CERES Study). [PDF]

Dermatol Ther (Heidelb)
Torres T, Sousa JT, Antunes J, Mendes-Bastos P, Brasileiro A, Neto V, Henrique M, Pimenta R, Magina S, Lourenço D, Mota F.   +10 more
europepmc   +1 more source